Novartis finds more uses for canakinumab
This article was originally published in Scrip
Executive Summary
Novartis’s anti-interleukin-1 beta inhibitor canakinumab (ACZ885) is looking promising in two rare periodic fever syndromes, show Phase II data presented this week at the American College of Rheumatology meeting in Washington DC.